

Overview

Useful For

Determining overexpression of HER2 protein on formalin-fixed, paraffin-embedded tissue sections in ductal carcinoma in situ or solid/intracystic papillary carcinoma breast tissue with a reflex to FISH testing if the specimen is equivocal (2+)

Reflex Tests

Test ID	Reporting Name	Available Separately	Always Performed
H2BR	HER2, Breast Tumor, FISH, Tissue	Yes	No

Testing Algorithm

Cases that are equivocal (2+) by immunohistochemical stain will reflex to *HER2* amplification by FISH at an additional charge.

Method Name

Ventana Pathway Immunoperoxidase Stain with Manual Quantitative Immunohistochemistry

NY State Available

Yes

Specimen

Specimen Type

Special

Ordering Guidance

This test is only for ductal carcinoma in situ or solid/intracystic papillary carcinoma breast tissue. For gastroesophageal cancer, order HERGM / HER2, Gastric/Esophageal, Semi-Quantitative Immunohistochemistry, Manual or HERGN / HER2, Gastric/Esophageal, Semi-Quantitative Immunohistochemistry, Manual, No Reflex.

Shipping Instructions

Attach the green pathology address label included in the kit to the outside of the transport container.

Necessary Information

Include accompanying pathology report stating the final diagnosis.

Specimen Required

Supplies: Pathology Packaging Kit (T554)

Specimen Type:

Preferred: A paraffin-embedded tissue block containing breast cancer tissue that has been fixed in 10% neutral buffered formalin within 1 hour from surgical collection time and for a total of 6 to 72 hours and shipped at ambient temperature

Acceptable: 5 Unstained sections containing breast carcinoma on charged slides cut at 4 microns less than 1 month ago and shipped at ambient temperature. Tissue on the slides should have been fixed in 10% neutral buffered formalin within 1 hour from surgical collection time and for a total of 6 to 72 hours.

Collection Instructions:

1. Submit paraffin-embedded ductal carcinoma in situ or solid intracystic papillary carcinoma breast carcinoma tissue.
2. Paraffin blocks will be returned with final report.

Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

[-Oncology Test Request \(T729\)](#)

[-Immunohistochemical \(IHC\)/In Situ Hybridization \(ISH\) Stains Request \(T763\)](#)

Specimen Minimum Volume

Entire specimen

Reject Due To

No specimen should be rejected.

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Special	Ambient (preferred)		
	Refrigerated		

Clinical and Interpretive

Clinical Information

The *HER2* (official gene name *ERBB2*) proto-oncogene encodes a membrane receptor with tyrosine kinase activity and homology to the epidermal growth factor receptor.

Amplification and overexpression of the *HER2* gene in human breast, endometrial, ovarian, and other epithelial cancers have been associated with a shorter disease-free interval and shorter overall survival. Overexpression of HER2 protein is an indication for Herceptin therapy in patients with breast cancer.

Reference Values

Reported as negative (0, 1+), equivocal (2+), and strongly positive (3+) according to the interpretation guidelines for the FDA-approved Ventana Pathway HER2 (4B5) antibody.

Interpretation

Results are reported as negative (0, 1+), equivocal (2+), and strongly positive (3+) according to the interpretation guidelines for the FDA-approved Ventana Pathway HER2 (4B5) antibody.

Cautions

The performance and quality of immunohistochemical stains in formalin-fixed, paraffin-embedded tissue depends critically on proper fixation.

Clinical Reference

1. Riber-Hansen R, Vainer B, Steiniche T: Digital image analysis: a review of reproducibility, stability and basic requirements for optimal results. *Apmis* 2012 April;120(4):276-289
2. Gavrielides MA, Gallas BD, Lenz P, et al: Observer variability in the interpretation of HER2/neu immunohistochemical expression with unaided and computer-aided digital microscopy. *Arch Pathol Lab Med* Feb;135(2):233-242
3. Cuadros M, Villegas R: Systematic review of HER2 breast cancer testing. *Appl Immunohistochem Mol Morphol* Jan 2009;17(1):1-7
4. Nassar A, Cohen C, Agersborg SS, et al: Trainable immunohistochemical HER2/neu image analysis: a multisite performance study using 260 breast tissue specimens. *Arch Pathol Lab Med* 2011 July;135(7):896-902

Performance

Method Description

Testing is performed using FDA-approved Ventana Pathway HER2 (4B5) rabbit monoclonal primary antibody and a proprietary detection system.(Package insert: PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody)

Scoring is performed according to ASCO/CAP guidelines as follows:

-Score of 3+ is defined as circumferential membrane staining that is complete, intense and in greater than 10% of invasive tumor cells

-Score of 2+ is defined as weak to moderate complete membrane staining observed and in greater than 10% of the invasive tumor cells; or circumferential membrane staining that is complete, intense and in less than or equal to 10% of invasive tumor cells

-Score of 1+ is defined as incomplete membrane staining that is faint or barely perceptible and in greater than 10% of the invasive tumor cells; or weak to moderate complete membrane staining observed and less than 10% of the invasive tumor cells

-Score of 0 is defined as no staining observed or membrane staining that is incomplete and is faint or barely perceptible and in less than or equal to 10% of the invasive tumor cells.(Wolff AC, Hammond ME, Hicks DG, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. [published online ahead of print May 30, 2018]. *J Clin Oncol*. doi: 10.1200/JCO.2018.77.8738.)

PDF Report

No

Day(s) Performed

Monday through Friday

Report Available

4 to 14 days

Specimen Retention Time

Until 1 week after results are reported. Materials made at Mayo Clinic may be retained at Mayo Clinic indefinitely.

Performing Laboratory Location

Rochester

Fees and Codes
Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact [Customer Service](#).

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

88360

LOINC® Information

Test ID	Test Order Name	Order LOINC Value
HERDM	HER BreastDCIS IHC Manual + Reflex	In Process

Result ID	Test Result Name	Result LOINC Value
70980	Interpretation	50595-8
70981	Participated in the Interpretation	No LOINC Needed
70982	Report electronically signed by	19139-5
70984	Material Received	81178-6
MA017	Tumor classification	21918-8
71623	Disclaimer	62364-5
71837	Case Number	80398-1